These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17140281)

  • 1. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Scott LJ
    CNS Drugs; 2006; 20(12):1027-52. PubMed ID: 17140281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
    Stimmel GL; Gutierrez MA; Lee V
    Clin Ther; 2002 Jan; 24(1):21-37. PubMed ID: 11833834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of intramuscular ziprasidone in the management of acute psychotic agitation.
    Mendelowitz AJ
    Ann Clin Psychiatry; 2004; 16(3):145-54. PubMed ID: 15517847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best clinical practice with ziprasidone IM: update after 2 years of experience.
    Zimbroff DL; Allen MH; Battaglia J; Citrome L; Fishkind A; Francis A; Herr DL; Hughes D; Martel M; Preval H; Ross R
    CNS Spectr; 2005 Sep; 10(9):1-15. PubMed ID: 16247923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone, a new atypical antipsychotic drug.
    Carnahan RM; Lund BC; Perry PJ
    Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
    Taylor D
    CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From clinical research to clinical practice: a 4-year review of ziprasidone.
    Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
    CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.
    Daniel DG; Copeland LF
    Expert Opin Investig Drugs; 2000 Apr; 9(4):819-28. PubMed ID: 11060712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
    Brook S
    J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
    Greenberg WM; Citrome L
    CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
    Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
    CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
    Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
    Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.